Ok//@koolgal:What a wonderful conclusion to 9 glorious days of learning the intricacies of investing in the US stock markets.  I have learnt so much thanks to @Tiger_Academy who is truly a master in this.  I will keep these lessons in mind when I invest in the US markets.   I am very grateful and appreciative of the time and effort by @Tiger_Academy in presenting the lessons in a clear and concise manner.On behalf of all my Dear Tiger Friends, we sincerely thank you @Tiger_Academy for the lessons learnt that will serve us

Ok//@daz88888888:$Immix Biopharma, Inc.(IMMX)$Immix Biopharma Inc. (NASDAQ: IMMX) was up 30% after the biopharmaceutical firm pioneering Tissue-Specific Therapeutics targeting immune-dysregulated and oncology diseases announced positive preliminary trial data showing that after one treatment cycle, its lead candidate IMX-110 had 75% survival compared to 0% survival for FDA-approved drug Trabectedin that is sold as YONDELIS.Trading DataOn Friday, IMMX stock gained 30.06% to $2.12 with more than 111.65 million shares, compared to its average volume of 2 million shares. The stock moved within a range of $2.0700 – 2.8700 after opening trade at $2.49.Key DetailsThe company compared IMX-110 against app

Like pls I will like back 

Like and comment please [Happy] 

Like and share and comment I will do the same 

Ouch